Pilot Study of Atorvastatin for Orthopedic Surgery Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2017-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Up to 35% of hip fracture patients have been shown to experience heart injury after surgery, and as many as 10% have a heart attack or die in the three months after surgery. Hip and knee arthroplasty patients are also at risk of cardiovascular complications. Patients who have these complications have higher levels of inflammation postoperatively. Statins (such as atorvastatin/Lipitor) lower cholesterol and also lessen inflammation. Both of these effects are important in preventing heart attacks. Statins have been shown to reduce the risk of heart attacks in non-surgical patients, and to protect from heart attacks in patients having heart surgery. Whether statins can prevent heart attacks in orthopedic patients is not known.

In this pilot study the investigators will treat 30 orthopedic surgery patients (hip fracture, hip or knee arthroplasty) with either atorvastatin or placebo (a capsule with no study drug). Patients will start the study drug prior to surgery and take it for 45 days after surgery. Neither the doctors nor the patients will know whether they are taking atorvastatin or placebo. The investigators will look for evidence of inflammation and heart injury after surgery. The investigators hypothesize that atorvastatin will lessen the degree of postoperative inflammation found in these patients. In this study, the investigators will use a very sensitive test of heart injury that can detect problems even when patients have no symptoms. The investigators hypothesize that this test will demonstrate silent heart injury in over 50% of the hip fracture patients and over 30% of arthroplasty patients in our study.

The results of this trial will help us to develop a larger study in 1000 hip fracture and joint replacement patients to determine whether atorvastatin protects orthopedic surgery patients from heart injury and other complications of surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Atorvastatin in Perioperative Vascular Surgery - Pilot Study

NCT00610545

Vascular Surgery

COMPLETED PHASE4

Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF)

NCT02029534

Cardiothoracic Surgery Post-operative Atrial Fibrillation

UNKNOWN PHASE4

Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose

NCT01543555

Myocardial Infarction Peripheral Vascular Disease Aortic Aneurism

COMPLETED PHASE3

The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation

NCT00579098

Atrial Fibrillation Arrhythmia Inflammation +1 more

COMPLETED PHASE4

Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study

NCT00756886

Arrhythmia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Thirty statin-naïve patients ≥ 65 years of age admitted to New York Presbyterian Hospital or Hospital for Special Surgery with an acute hip fracture, or for elective hip or knee arthroplasty will be randomized in a 1:1 ratio to atorvastatin 40 mg daily or matching placebo.
* Atorvastatin will be initiated at least 4 hours prior to hip fracture surgery, or 4 days prior to arthroplasty, and will be continued until postoperative day (POD) 45.
* Patients will be assessed daily in the hospital for adverse events.
* Patients will be contacted by telephone weekly for four weeks after surgery and again on POD 45 and POD 90.
* Patients will mail back study medication bottles on POD 45 for pill counts to assess compliance.
* High sensitivity cardiac troponin I (hs-cTnI) will be measured pre-operatively (prior to atorvastatin therapy) and on POD 2.
* High sensitivity C-reactive protein (hs-CRP), and a panel of cytokines (IL-1β, IL-2, IL-2r, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and soluble (s)CD-40L) will be measured preoperatively and on POD 2.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hip Fracture Myocardial Ischemia Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Atorvastatin

Atorvastatin 40mg daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.

Group Type EXPERIMENTAL

Atorvastatin

Intervention Type DRUG

Atorvastatin or placebo will be started at least 4 hours prior to surgery, and continued nightly until postoperative day 45

Sugar pill

Sugar pill (placebo) daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atorvastatin

Atorvastatin or placebo will be started at least 4 hours prior to surgery, and continued nightly until postoperative day 45

Intervention Type DRUG

Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lipitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hip fracture or elective hip or knee arthroplasty
* Age 65 years or older
* Life expectancy \> 3 months

Exclusion Criteria

* Pathological hip fracture due to cancer
* Currently taking a statin, or took a statin within the last 30 days
* Previous statin intolerance
* Acute myocardial infarction or unstable angina
* History of myocardial infarction, acute coronary syndrome, angina, coronary/arterial re-vascularization
* Hip fracture patients with peripheral arterial disease
* Hip fracture patients with history of stroke or transient ischemic attack.
* Muscle disorder
* Serious liver disease or alanine aminotransferase \> 3x upper limit of normal
* Serious renal disease (creatinine clearance \<30cc/min)
* Treatment with HIV protease inhibitor or Hepatitis C protease inhibitor
* Treatment with erythromycin, clarithromycin, niacin or azole antifungal agent
* Pregnant, planning to become pregnant, or breastfeeding

Minimum Eligible Age

65 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No